Background Clinical trials have demonstrated galcanezumab as safe and effective in
migraine prevention. However, real-life data are still lacking and overlook the impact of …

Objective The relative effects of monoclonal antibody against calcitonin gene-related
peptide (CGRP) or its receptor for adult migraine patients with prior treatment failure remains …

Objective To evaluate the efficacy and safety of galcanezumab in patients with migraine in a
real-world setting in Japan. Background Galcanezumab is the first anti-calcitonin gene …

Background Trigeminal neuralgia is a severe facial pain disorder that is difficult to treat.
Erenumab, a monoclonal antibody against the calcitonin gene-related peptide (CGRP) …

Introduction Chronic headache due to the overuse of medication for the treatment of
migraine attacks has a prevalence of 0.5–2.0%. This guideline provides guidance for the …

Migraine is a leading cause of disability worldwide. A minority of individuals with migraine
develop resistant or refractory conditions characterised by≥ 8 monthly days of debilitating …

Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …

Remarkable advancements have been made in the field of migraine pathophysiology and
pharmacotherapy over the past decade. Understanding the molecular mechanism of …

Abstract Aim Serum levels of Calcitonin Gene-Related Peptide (CGRP)-like
immunoreactivity (CGRP-LI) in migraine patients before and after starting treatment with …

Objective To provide a position statement update from The American Headache Society
specifically regarding therapies targeting calcitonin gene‐related peptide (CGRP) for the …